VAXXON SRP E. COLI
Commercial- Indications
- Bacterial infections in livestock
Company intelligence / Profile preview
Vaxxinova’s SRP® technology-based vaccines have been commercialized for multiple livestock pathogens. The company recently achieved USDA approval for the first-ever importation of a live avian metapneumovirus vaccine into the U.S., marking a significant regulatory milestone. No human clinical trials as this is an animal health company.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vaxxinova.